Aaron Deykin
Chief Medical Officer and Head of Research & DevelopmentMr. Aaron Deykin, M.D. serves as Director of GentiBio, Inc. since 2023. He serves as Chief Medical Officer and Head of Research & Development at Upstream Bio Inc. since April 2022. Mr. Deykin leads the company’s development vision, providing clinical expertise, translational science direction, regulatory strategy, product development and a strategic roadmap, driving Upstream Bio’s innovative programs to approval. He was Senior Vice President of Clinical Sciences overseeing Biostatistics, Statistical Programming, Biomarkers, Clinical Pharmacology, Epidemiology and Clinical Operations for Biogen’s pipeline globally. Mr. Deykin was a Vice President, Head of Multiple Sclerosis and Acute Neurology Late Stage Clinical Development Unit at Biogen Inc. Prior to moving to industry in 2006, he was Assistant Professor of Medicine at Harvard Medical School and a member of the Pulmonary and Critical Care faculty at Brigham and Women’s Hospital. In that capacity, Aaron treated patients with asthma and other advanced respiratory diseases while leading the medical activities of the Lung Transplantation Program, directing the Pulmonary Function Testing Laboratory and serving as the Associate Director of the Asthma Research Center. Aaron has been awarded board certification in Internal Medicine, Pulmonary Disease and Critical Care Medicine and holds an MD from Harvard Medical School and an AB from Dartmouth College.
Positions
- Company NameUpstream Bio, Inc.Stock CodeUPBPositionChief Medical Officer and Head of Research & DevelopmentColleagues
- ERE. Rand SutherlandCEO & Director
- RCRonald C. RenaudIndependent Chairman of the Board
- MPMichael Paul GrayCFO & COO
- SPStacy PriceChief Technology Officer
- MBMeggan BuckwellDirector of Corporate Communications & Investor Relations
- MKMarcella Kuhlman RuddyIndependent Director
- DBDaniella BeckmanIndependent Director
- ECErez ChimovitsIndependent Director
